ACCEPTING CASES NATIONWIDE

585.287.8188

CALL US

CONTACT US

Written By: Robert King, Esq.
Legal Review By: Daniel Nigh, Esq.
Legal Review By: Jerry King, Esq.
The Mounjaro Vision Loss Lawsuit is Active
See If You Qualify

Some patients taking Mounjaro (tirzepatide) to help control their type 2 diabetes have experienced NAION, a condition that often causes blurred vision in one eye. This serious condition is often irreversible, and many patients say they were not warned that Mounjaro could increase their risk of NAION.

Some patients are pursuing lawsuits against Mounjaro’s manufacturer, Eli Lilly. By filing lawsuits, patients who experienced vision loss after taking Mounjaro are trying to recover compensation for their injuries and the long-term impacts of having their vision compromised. Some plaintiffs are now filing personal injury claims as part of a multidistrict litigation (MDL) for people alleging vision loss from GLP-1 drugs. The MDL is called the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL 3163).

About the Mounjaro Eye Side Effects & Vision Loss Lawsuit:

Mounjaro Vision Loss Lawsuit Overview

Lawsuits filed against the manufacturer of Mounjaro, Eli Lilly and Company, allege that the company failed to warn users about the increased risk of sudden vision changes caused by nonarteritic anterior ischemic optic neuropathy (NAION). Some Mounjaro patients report developing serious eye problems, including NAION, which typically causes sudden and irreversible blindness.

Plaintiffs in Mounjaro vision loss lawsuits allege that they were not warned about a possible link between Mounjaro and vision loss. In fact, until recently, there was no such warning on Mounjaro’s drug prescribing label. Now, patients who experienced vision loss from NAION are seeking damages from Eli Lilly, alleging the company should have done more to warn patients and their physicians.

About the MDL for NAION from Mounjaro and Other GLP-1 Drugs

In December of 2025, the Judicial Panel on Multidistrict Litigation centralized some lawsuits alleging NAION caused by GLP-1 drugs, including those made by Eli Lilly. This MDL allows some plaintiffs to transfer their lawsuits into a centralized litigation. An MDL can benefit people filing Mounjaro NAION lawsuits by decreasing plaintiff responsibilities during some phases of the litigation and allowing for individualized settlements, should they be negotiated. King Law is actively representing plaintiffs in this MDL.

GLP-1 Vision Loss Lawsuit: MDL 3163 Key Information
Official MDL NameIn re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
MDL Number3163
Date CreatedDecember 15, 2025
CourtU.S. District Court for the Eastern District of Pennsylvania
Presiding JudgeU.S. District Judge Karen Spencer Marston
Master Docket Number2:25-md-03163
Type of LitigationFederal multidistrict product liability litigation (not a class action)
Alleged InjuryNon-arteritic anterior ischemic optic neuropathy (NAION), potentially resulting in permanent vision loss
Defendants IdentifiedNovo Nordisk entities and Eli Lilly and Company
Primary Legal AllegationsFailure to warn, defective product design, and breach of warranty
Related LitigationMDL 3094, involving gastrointestinal injury allegations associated with GLP-1 drugs

Mounjaro and Vision Changes – 2026 Update

November 2026: The FDA is requiring drug manufacturers to update the warning label on Mounjaro and similar drugs to include the potential increased risk of patients developing NAION when taking GLP-1 products. The FDA made this decision after reviewing medical research and adverse event reports that suggested a potential increased risk.

There are 278 active lawsuits in the MDL about the potential link between taking Mounjaro or another GLP-1 product and developing NAION, which can cause eye side effects.

October 2026: On October 20, 2026, the MDL judge entered an order discussing the Plaintiff Fact Sheets that GLP-1 patients must submit if they file a NAION claim in the MDL. The case count for the MDL about whether GLP-1 products (such as Mounjaro) increase the risk of NAION has risen by 31 as of October 1, 2026. According to the JPML’s report, there are now 247 pending claims in the GLP-1 NAION MDL.

September 2026: As of September 1, 2026, there are 216 lawsuits in the MDL about whether GLP-1 products like Mounjaro may increase the risk of NAION. On September 1, 2026, a man from Louisiana filed a lawsuit against Eli Lilly, the company that manufactures Mounjaro, and one other GLP-1 company. According to his complaint, he has lost his eyesight in his right eye after suffering from non-arteritic anterior ischemic optic neuropathy (NAION). He believes that taking Mounjaro and one other GLP-1 product may have caused him to develop NAION and experience eye side effects that led to permanent vision loss and other profound setbacks.

Read Previous Updates About Mounjaro Vision Loss Lawsuits

What Is NAION?

Research now indicates that GLP-1 receptor agonists, like Mounjaro, may be linked to a serious and potentially irreversible eye condition known as NAION. This eye condition is characterized by decreased blood supply to the optic nerve and is sometimes referred to as an eye stroke in layperson terms. The optic nerve is a bundle of fibers that connects the eye to the brain, enabling vision. The condition, frequently referred to as a “stroke of the optic nerve,” causes a restriction of blood flow and can lead to sudden vision loss.

NAION is the most common form of optic nerve damage in people over 50. It has an estimated annual incidence rate between 2.3 and 10.2 per 100,000 people over 50 years of age in the United States. Recent studies have found that patients with type 2 diabetes taking a GLP-1 receptor agonist (such as Mounjaro) may be at an increased risk for developing the debilitating condition. Patients who develop NAION may have permanent, irreversible vision loss and are encouraged to seek legal consultation.

This infographic explains what the main vision problem is while taking Mounjaro and briefly describes the issue. It also explains how Mounjaro can affect vision. Image of a Mounjaro injection pen.

Mounjaro and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Multiple scientific studies have explored a possible association between using a GLP-1-RA drug like Mounjaro and an increased risk of developing NAION. Additionally, in November 2026, the FDA required Eli Lilly and other GLP-1-RA drug manufacturers to add a statement about NAION to drug warning labels. Now, Mounjaro and other GLP-1 drugs carry a warning for a possible increased risk of NAION for some patients.

FDA-Mandated Label Change for Mounjaro and NAION

FDA Requires New NAION Warnings for Mounjaro and Other GLP-1 Drugs

Prior to November 2026, Mounjaro’s prescribing label did not include a warning about the potential increased risk of developing NAION, a condition that can cause sudden, permanent vision loss.

On November 9, 2026, the FDA issued a Drug Safety Communication warning patients and healthcare professionals about the potential increased risk of NAION associated with GLP-1 receptor agonist medications, including Mounjaro (tirzepatide).

The FDA is requiring manufacturers of all GLP-1 receptor agonist medications to add information about this potential risk to the Warnings and Precautions section of their prescribing labels.

Source:

FDA Drug Safety Communication, November 9, 2026

Studies Exploring Possible Link Between NAION and GLP-1 Drugs Like Mounjaro

A study published in JAMA Ophthalmology in July 2024 indicates that patients with type 2 diabetes who are taking GLP-1 receptor agonists may be at an increased risk for developing a serious and debilitating condition known as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). NAION occurs when there is insufficient blood supply to the head of the optic nerve. The reduced blood flow can cause sudden vision loss, which usually occurs without warning and is painless. Risk Factors include age (it usually affects people over 50), diabetes, hypertension, high cholesterol, sleep apnea, and anatomical predispositions such as a small cup-to-disc ratio.

Study Finding: Researchers Identify Higher NAION Risk Among GLP-1 Drug Users

In July 2024, researchers at Mass General Brigham published a study examining 16,827 patient records. They found that patients prescribed semaglutide (Ozempic or Wegovy) had a higher estimated incidence of NAION than patients prescribed certain other medications.

Estimated NAION incidence over three years:

  • Patients with type 2 diabetes: 8.9% for those prescribed semaglutide compared with 1.8% for those prescribed other medications.
  • Patients with overweight or obesity: 6.7% for those prescribed semaglutide compared with 0.8% for those prescribed other medications.

After statistical adjustments, the researchers identified approximately 4.3 times the hazard of NAION in the diabetes group and 7.6 times the hazard in the overweight or obesity group.

What this means for Mounjaro patients: Mounjaro contains tirzepatide, not semaglutide. Although both medications act on GLP-1 receptors, these findings do not establish the incidence or degree of NAION risk associated with Mounjaro.

Source:
Hathaway et al., Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide, JAMA Ophthalmology (2024).

Study Finding: Danish Researchers Report More Than Twice the Hazard of NAION

A nationwide Danish study published in December 2024 examined 424,152 people with type 2 diabetes. Researchers investigated whether once-weekly semaglutide use was associated with an increased likelihood of developing NAION, a condition that can cause sudden vision loss.

Key findings included:

  • 218 patients developed NAION during the study period.
  • 67 of those patients had been exposed to semaglutide.
  • After adjusting for other factors, researchers found approximately 2.2 times the hazard of NAION among patients exposed to semaglutide.

Although the researchers identified an increased relative risk, NAION remained uncommon in the population studied.

What this means for Mounjaro patients: This study adds to concerns about possible vision-related complications involving GLP-1 medications. However, it specifically evaluated semaglutide and did not determine whether patients taking Mounjaro face a similar increase in risk.

Source:
Grauslund et al., Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes, International Journal of Retina and Vitreous (2024).

Study Finding: Large Analysis Links Semaglutide to a Modest Increase in NAION Risk

A 2025 study published in JAMA Ophthalmology evaluated health information covering 37.1 million adults with type 2 diabetes, including more than 810,000 new semaglutide users. The researchers investigated whether semaglutide exposure was associated with NAION and how frequently the condition occurred.

Researchers reported:

  • 32% higher NAION incidence rate during semaglutide exposure using a broader diagnostic definition.
  • 50% higher incidence rate using a stricter definition of NAION.
  • 14.5 NAION cases per 100,000 person-years among semaglutide users under the broader definition.

The increased rates came from analyses comparing periods of exposure and nonexposure. Comparisons with other diabetes medications did not consistently identify a statistically significant increase in risk. Researchers concluded that semaglutide may be associated with a modest increase in NAION risk.

What this means for Mounjaro patients: The study provides additional evidence of a possible relationship between certain GLP-1 medications and NAION. However, its findings cannot be used to calculate the risk for people taking Mounjaro, which contains a different active ingredient.

Source:
Cai et al., Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy, JAMA Ophthalmology (2025).

Other Vision Problems Associated with Diabetes and Mounjaro

In addition to the side effects listed above, Mounjaro patients may also be at risk for other eye injuries, such as blurry vision caused by blood sugar fluctuations and diabetic retinopathy as a result of poorly controlled diabetes.

Other vision problems people can experience while taking Mounjaro:

  • Blurry Vision: Fluctuations in blood sugar levels may affect the lens shape of the eye, causing temporary vision changes, such as blurry vision, until glucose levels stabilize.
  • Diabetic Retinopathy: Diabetic retinopathy is a common complication of diabetes where high blood sugar levels damage the retina’s blood vessels. While Mounjaro helps manage blood sugar levels, the risk remains if levels are not well-controlled, making regular eye exams crucial.
  • Macular Edema: Poorly controlled diabetes can cause fluid leakage into the macula (the central part of the retina responsible for detailed vision). Mounjaro can help manage blood sugar but cannot eliminate the risk of macular edema or swelling in the macula if diabetes is inadequately controlled.
  • Visual Disturbances: Defined as changes in color perception, seeing flashes of light, or other unusual visual phenomena, visual disturbances could result from blood sugar fluctuations, blood pressure changes, or other systemic effects of Mounjaro.
  • Ocular Migraines: Ocular migraines involve visual disturbances such as flashing lights, zigzag patterns, or temporary vision loss. They are potentially triggered by stress, hormonal changes, or medications affecting blood vessels, though the exact cause is unclear.

This infographic lists the possible eye side effects while taking Mounjaro, noting the symptoms of NAION. Image of a young black man getting his eyes examined by an older white man.

Mounjaro Vision Loss Lawsuit Eligibility

People who took Mounjaro and were diagnosed with NAION may qualify to file a lawsuit as part of MDL 3163. Patients who lost vision in one or both eyes and were later diagnosed with NAION may qualify. Here are some records that patients can collect to support their eligibility for a NAION claim:

  • Medical records related to their NAION diagnosis
  • Pharmaceutical records for Mounjaro prescriptions
  • Treatment records
  • Proof of lost wages
  • Personal and witness statements about impacts of vision loss on one’s quality of life
  • Documentation of all financial losses and costs related to the NAION diagnosis
  • Witness reports from friends and family

Our team at King Law can help clients retrieve these records. They will advise on when to collect the records and necessary documentation to support a claim. We can help clients track down personal records that will support their claim.

How to File a Mounjaro Vision Loss Lawsuit

Patients taking Mounjaro who experience vision loss caused by NAION are encouraged to contact an attorney to discuss whether they have a valid claim for compensation. Here are the steps someone can take if they are considering filing a claim for vision loss after Mounjaro:

  1. Contact an Attorney: The first step in a Mounjaro lawsuit is to determine eligibility. Eligibility requirements may include proof of Mounjaro usage and the ability to show that your eye injuries were caused by the medication. To see if you meet the qualifications, it is recommended that you speak to an attorney. During the free case review, an attorney will help assess the validity and value of your claim. They will also help manage the legal process.
  1. Gather Evidence: An attorney can aid you in collecting evidence that may help to substantiate your claim, including medical records and witness testimonies.
  1. File the Claim: Once the evidence is collected, your attorney will file the claim in the appropriate jurisdiction. They will ensure that all legal requirements are met, including adhering to the statutes of limitations or state-specific deadlines that may apply to your case.
  1. Enter into Negotiations: Once the case is filed, the lawsuit may enter the Discovery phase. Your attorney may also enter into negotiations with the other party to achieve a fair and full settlement. If a reasonable settlement cannot be reached, the case may go to trial.
  1. Prepare for Trial: At trial, both parties will be able to present their case. If the results are unfavorable, the decision may be appealed.

As a client, it is important to supply your attorney with your full medical records and provide supporting documentation. Then, you should allow the law firm to represent you and file the claim in the appropriate courthouse.

This infographic shows the most basic steps of a Mounjaro eye side effects lawsuit and lists example of evidence that will support your claim.

Contact King Law to Discuss Your Mounjaro Vision Loss Case

Were you diagnosed with NAION after you started taking Mounjaro? You may be eligible to file a claim against the manufacturer, Eli Lilly and Company. At King Law, our attorneys have extensive experience handling Mounjaro lawsuits and pursuing compensation on our clients’ behalf. Contact our office today to schedule a free, no-obligation consultation.

Previous Updates About Mounjaro Vision Loss Research & Lawsuits

Here are previous lawsuit, regulatory, and research updates related to Mounjaro and NAION.

Updates from Earlier in 2026

August 2026: A new observational study found that patients in the US insurance database who had diabetes and started a GLP-1 product (like Mounjaro) had an increased risk of developing ischemic optic neuropathy (ION) within 18 months. However, the risk of ION was still rare. As of August 3, 2026, there are 200 lawsuits that have been consolidated in the federal MDL about whether Mounjaro and other GLP-1 products may be associated with a higher risk of vision problems due to NAION.

On August 27, 2026, the judge entered an order scheduling important deadlines to help the MDL move forward. One of those is a deadline for when the plaintiffs must turn in their fact sheets, which provide the court with information about who they are, when they took Mounjaro (or another GLP-1), and what injuries they suffered because of it.

July 2026: There are currently 146 pending claims in the MDL for patients alleging that GLP-1 drugs, including Mounjaro, led them to develop NAION (vision loss). Meanwhile, an observational study published in May suggests that people with Type 2 diabetes who take a GLP-1 (like Mounjaro) may have an increased risk of developing NAION. Patients in the dataset had a 2.56 times higher rate of developing NAION within 1 year after starting a GLP-1 receptor agonist than those in the dataset who started a dipeptidyl peptidase-4 (DPP-4) inhibitor. GLP-1 patients in the dataset had an even higher risk if they were younger, male, had smoked in the past, and had a marked decrease in their A1C levels. However, the overall risk of developing NAION was low (about 11.3 cases for every 100,000 patients).

The Therapeutic Goods Administration of Australia has added a warning about the possible risks of developing NAION when taking some types of GLP-1 drugs. The TGA found that the evidence studied suggested an association between semaglutide and NAION, and the TGA’s review found that some patients who took other types of GLP-1 drugs also experienced NAION. The TGA decided there was enough evidence to issue a class warning for GLP-1 drugs, including tirzepatide (Mounjaro’s active ingredient).

June 2026: There are 110 lawsuits that have been filed or transferred into the GLP-1 NAION MDL, an increase of 24 from May’s case count. Meanwhile, some Mounjaro patients in France who are taking Mounjaro for obesity may be eligible for partial reimbursement of its cost under a state law. This could make the medication more accessible to patients.

May 2026: Another 13 lawsuits have joined the multidistrict litigation alleging that Mounjaro and other GLP-1s may be associated with a risk of an eye stroke called NAION. A total of 86 of these cases has been filed or transferred into the federally-based MDL. NAION can come on suddenly, have little to no warning signs, and result in permanent vision loss in one or both eyes. Some of the Mounjaro lawsuits allege that Eli Lilly was aware of these alleged eye side effects and should have told people about them.

April 2026: The newly consolidated NAION multidistrict litigation has 73 cases in its docket as of April 1, 2026. This is an increase of about 19 NAION lawsuits that have been filed by people who claim that they suffered from an eye stroke after taking Mounjaro or another type of GLP-1 product. Some of these lawsuits allege that Eli Lilly was aware of the potentially increased risk of patients developing sudden blindness after taking Mounjaro. Some plaintiffs who have filed lawsuits allege that Eli Lilly should have warned them about Mounjaro and a possible association with vision loss caused by NAION.

In scientific updates, a new study (GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy) suggests that taking a GLP-1 may be associated with an increased risk of developing NAION, a type of eye stroke that can cause sudden, permanent blindness. The study included 588,168 participants. 139,546 of those participants had type 2 diabetes and took a GLP-1. According to the results, the GLP-1 group was more likely to be diagnosed with NAION than the control group, which was prescribed sodium-glucose cotransporter-2 inhibitors. The association between taking a GLP-1 and being diagnosed with an eye disorder was not higher for other types of disorders, such as diabetic retinopathy. Some people who took Mounjaro have developed NAION and have filed lawsuits against Eli Lilly, accusing the company of not warning about the possible connection.

March 2026: A Science Day has been scheduled for the federal GLP-1 NAION litigation, which includes allegations against Eli Lilly’s Mounjaro. U.S. District Judge Karen Spencer Marston has scheduled the Science Day for MDL 3163 (Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation) for June 2, 2026. Science Days are important events in multidistrict litigations. During the session, attorneys representing plaintiffs and defendants present medical and scientific evidence to a judge in an educational manner. There is typically no cross-examination. These sessions help judges understand the scientific framework of the litigation. Plaintiffs’ attorneys typically present scientific information supporting the claimed injury. For this case, plaintiffs’ attorneys will likely present scientific research exploring the possible association between Mounjaro and other GLP-1 drugs and vision loss related to NAION.

As of March 2, 2026, there are 54 eye side effects lawsuits in the consolidated MDL involving Mounjaro and other GLP-1 drugs. This is an uptick of about 17 from February’s case count. The number of NAION lawsuits may continue to grow as Mounjaro patients who lost their vision begin to suspect that Mounjaro may be to blame.

February 2026: A woman in Indiana says she went blind in her right eye after taking Mounjaro. According to reporting from December 2025, she can still see out of her left eye, and she believes it is because her doctors told her to stop taking her GLP-1 when she lost sight in her other eye. The woman says she did not experience any pain or warning signs before she woke up and could not see out of her right eye. Although rare, other patients taking Mounjaro and other GLP-1s have experienced this same eye side effect. Enough plaintiffs have come forward and filed lawsuits that a federal NAION MDL was formed in December 2025. As of February 2, there are 37 pending lawsuits in MDL -3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation. This litigation represents people alleging eye injuries from Mounjaro and other GLP-1 drugs. Mounjaro patients can speak with an attorney about joining this litigation if they have also suffered vision loss.

January 2026: Now that an MDL has been created for those who have experienced vision loss after taking Mounjaro and other GLP-1 drugs, the court will be taking several steps to advance the litigation. The early stages of an MDL will include the judge overseeing the MDL (Judge Marston) appointing attorneys to lead the centralized litigation. Then, attorneys on both side will gather scientific evidence and work with experts to support and counter the claims in the case. Then, parties on both sides will exchange information in a process called discovery. Although the MDL process is currently very early, people diagnosed with NAION (sudden and mostly permanent vision loss) after taking Mounjaro now have a path forward to pursuing compensation.

Updates from 2025

December 2025: The Judicial Panel on Multidistrict Litigation (JPML) has approved a new group lawsuit for people who experienced vision loss after taking Mounjaro and other GLP-1s. The new MDL is entitled IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, and is MDL Number 3163. The new case will be heard by the same judge overseeing another MDL about GLP-1s, Karen Marston. However, this MDL will solely be for people who took a GLP-1 (like Mounjaro) and developed a rare eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION). NAION can occur suddenly and result in complete vision loss in one or both eyes. Mounjaro patients say they were not warned that NAION could happen to them, and they are suing Eli Lilly. This MDL is active, and new plaintiffs can pursue joining if they experienced eye side effects after taking Mounjaro.

The WHO is encouraging countries to make Mounjaro available to more people, potentially opening the door to a surge in the number of Mounjaro-related cases of vision loss worldwide. Mounjaro, also known by its generic name, tirzepatide, is a drug of choice for many looking to lose weight or treat their type 2 diabetes. However, Mounjaro can also cause sudden vision loss brought on by a type of ministroke in the artery leading to the optic nerve. Mounjaro patients who have lost their sight say they were not told this was a potential concern when taking the drug. Many of those patients are filing lawsuits.

On December 4, 2025, the Judicial Panel on Multidistrict Litigation (JPML) heard arguments for creating a group lawsuit for people who lost their vision after taking Mounjaro and other GLP-1 drugs. Mounjaro’s manufacturer, Eli Lilly, submitted the motion to create this multidistrict litigation (MDL). This group lawsuit would be a separate MDL from people alleging other injuries due to GLP-1 drugs. If the motion is approved, people who are diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) after taking Mounjaro will be able to benefit from the consolidations made in a group litigation. People can retain an attorney now for this litigation.

November 2025: Although vision loss is an uncommon side effect of tirzepatide drugs like Mounjaro, some people who take the drug experience this life-altering side effect. A mechanic from New Jersey experienced vision loss related to Mounjaro. James Norris who took Mounjaro to treat several health conditions related to obesity. Norris ended up being diagnosed with NAION, a type of vision loss due to inflammation of nerves in the eye. Norris is now unable to perform work as a hands-on mechanic, and his vision is permanently altered. He filed a lawsuit against Eli Lilly for not warning him of the vision-loss side effects of Mounjaro.

October 2025: Multiple studies have connected Mounjaro and other GLP-1 drugs with eye side effects and vision loss. Two studies looked at the vision outcomes for people with Type 2 diabetes who take Mounjaro and other GLP-1 medications over a two-year period. Both studies found that people who took GLP-1s had worse vision outcomes than those who did not. Mounjaro patients across the United States have noticed blurred or complete loss of vision and other eye side effects after they started taking Mounjaro. They have been filing lawsuits in federal and state courts because they were not warned of this risk.

September 2025: In an unusual move for a defendant, Eli Lilly and other defendants listed in the GLP-1 drug group lawsuit have asked for another group lawsuit against the drugs to be formed. After more studies support a link between tirzepatide drugs like Mounjaro and vision loss, drug companies are using an uncommon tactic. Eli Lilly and other defendants have asked for another multidistrict litigation (MDL) to be formed in New Jersey federal courts. There is already an MDL in this court for people who experienced stomach and intestinal injuries from Mounjaro and other GLP-1 drugs. Meanwhile, another study published in the Journal of the American Medical Association (JAMA) has found that taking tirzepatide drugs like Mounjaro doubles a person’s risk of NAION. This eye-related side effect causes vision loss and blurred vision that is typically permanent.

August 2025: A growing body of scientific research says that Mounjaro and other GLP-1 drugs may lead to dangerous side effects that affect vision. Some people who took Mounjaro have developed NAION (nonarteritic anterior ischemic optic neuropathy), which causes sudden and mostly irreversible blindness. Now, people harmed in this way may be able to join a group litigation in the state of New Jersey. A judicial panel is reviewing the need to create a multicounty litigation (MCL), which is a type of group lawsuit. If this MCL is created, people who experienced vision loss after taking Mounjaro will have new legal options.

June 2025: A 2025 study published in JAMA Ophthalmology has found a connection between taking tirzepatide drugs like Mounjaro and developing NAION. NAION stands for nonarteritic ischemic anterior optic neuropathy. This condition is a type of eye stroke that often leads to permanent vision loss. The authors of the study hypothesize the rapid correction of blood sugar that tirzepatide causes leads to swelling in the optic nerve and NAION.

Updates from 2024

July 2024: A study linking patients with type 2 diabetes who were taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to an increased risk of a rare and serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION). The study was published in JAMA Ophthalmology on July 3, 2024.

June 2024: Mounjaro manufacturer issued an Open Letter warning patients against using the drug for cosmetic weight loss and counterfeit versions of the drug. The letter also noted that individuals who experience changes in vision while taking the medication should contact their healthcare provider.

Frequently Asked Questions (FAQs)

What is the Mounjaro eye side effects lawsuit about?
New research indicates that GLP-1 receptor agonists, such as Mounjaro, may increase a person’s risk for developing a serious and irreversible eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION). NAION can cause sudden, painless vision loss in one eye.
What is the basis for the Mounjaro eye side effects lawsuit?
Lawsuits allege that the manufacturer of Mounjaro, Eli Lilly, knew of the risks of serious side effects associated with using the drug and failed to warn consumers about the dangers.
Can Mounjaro cause vision changes?
In November 2026, the FDA mandated that a warning about an increased riskk of NAION be added to Mounjaro’s and other GLP-1 drugs’ labels.
Does Mounjaro cause blurry vision?
Mounjaro may increase someone’s chance of developing NAION, which typically causes blurred vision in one eye.
Who is at risk of developing NAION while using Mounjaro?
Anyone taking Mounjaro may be at increased risk of NAION. However, some studies suggest that people taking it for type 2 diabetes may have a higher risk than people taking it off-label for weight loss.
What steps should I take if I experience vision problems while taking Mounjaro?
If you are experiencing vision problems while taking Mounjaro, it is strongly recommended that you contact your healthcare provider immediately. Routine monitoring can help ensure you receive prompt treatment for any side effects.
What information do I need to provide to my attorney for the Mounjaro eye side effect lawsuit?
Information that you need to provide to your attorney for the Mounjaro eye side effect lawsuit includes medical records and proof of Mounjaro usage.
What evidence is needed to support a Mounjaro eye side effect lawsuit?
Evidence needed to support a Mounjaro eye side effect lawsuit includes your medical records, prescription history, studies showing side effects or complications of taking the drug, expert testimony, and other documents that can help prove the connection between the drug and your eye conditions.
How long do I have to file a lawsuit for NAION related to Mounjaro?
Mounjaro lawsuits are subject to a state-specific statute of limitations. The amount of time you have to file the case will depend on this statute but may be affected by other factors, including when you discovered the injuries.